Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-221 in healthy volunteers
NCT04404023Phase 1Unknown
- Sponsor
- United BioPharma
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of ub-221 in chronic spontaneous urticaria (CSU) (5 arms), sponsored by United BioPharma. Primary endpoint: Adverse event incidence at 15 days. Status: unknown.
02
Drugs
ub-221
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04404023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404023.